Cite
HARVARD Citation
Sasse, S. et al. (2022). AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leukemia & lymphoma. 63 (8), pp. 1871-1878. [Online].